Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lessened its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 42.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 115,476 shares of the company's stock after selling 83,811 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Roivant Sciences were worth $1,318,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. TOMS Capital Investment Management LP purchased a new position in shares of Roivant Sciences in the third quarter worth $46,333,000. FMR LLC increased its position in shares of Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after acquiring an additional 2,593,910 shares during the period. Geode Capital Management LLC increased its position in shares of Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after acquiring an additional 1,460,205 shares during the period. State Street Corp lifted its position in Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company's stock worth $225,737,000 after acquiring an additional 1,118,561 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Roivant Sciences by 49.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company's stock worth $26,625,000 after acquiring an additional 762,953 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares of the company's stock, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,875,586 shares of company stock valued at $21,491,661. Company insiders own 7.90% of the company's stock.

Analysts Set New Price Targets

ROIV has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of "Buy" and an average price target of $18.08.

Roivant Sciences Stock Down 1.6 %

Shares of NASDAQ ROIV traded down $0.18 during midday trading on Friday, reaching $10.79. 15,634,196 shares of the stock were exchanged, compared to its average volume of 5,629,099. The firm has a 50-day simple moving average of $10.78 and a two-hundred day simple moving average of $11.48. Roivant Sciences Ltd. has a twelve month low of $9.93 and a twelve month high of $13.06. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of -71.93 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.